653 related articles for article (PubMed ID: 19721208)
1. [Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus].
Azuma K
Clin Calcium; 2009 Sep; 19(9):1345-52. PubMed ID: 19721208
[TBL] [Abstract][Full Text] [Related]
2. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
3. [Absolute risk for fracture and WHO guideline. Treatment of patients with secondary osteoporosis].
Yamauchi M;
Clin Calcium; 2007 Jul; 17(7):1106-13. PubMed ID: 17607079
[TBL] [Abstract][Full Text] [Related]
4. [Primary osteoporosis--its diagnosis and treatment].
Inaba M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():485-9. PubMed ID: 18161153
[No Abstract] [Full Text] [Related]
5. [Up-to-date treatments for osteoporosis].
Bors K
Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
[TBL] [Abstract][Full Text] [Related]
6. [Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].
Tanaka I; Oshima H
Nihon Rinsho; 2009 May; 67(5):915-20. PubMed ID: 19432109
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options in osteoporosis.
Dominguez LJ; Scalisi R; Barbagallo M
Acta Biomed; 2010; 81 Suppl 1():55-65. PubMed ID: 20518192
[TBL] [Abstract][Full Text] [Related]
8. [Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].
Saito M
Clin Calcium; 2010 Mar; 20(3):345-54. PubMed ID: 20190364
[TBL] [Abstract][Full Text] [Related]
9. [Absolute risk for fracture and WHO guideline. Pharmacological intervention to prevent osteoporotic fractures in the elderly].
Hosoi T;
Clin Calcium; 2007 Jul; 17(7):1098-104. PubMed ID: 17607078
[TBL] [Abstract][Full Text] [Related]
10. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
Gorai I;
Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
[TBL] [Abstract][Full Text] [Related]
11. [Progress in the treatment of osteoporosis].
Sugimoto T
Rinsho Byori; 2008 Oct; 56(10):887-93. PubMed ID: 19068785
[TBL] [Abstract][Full Text] [Related]
12. [Drug treatment for the treatment of primary osteoporosis].
Halbekath J
Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):453-60. PubMed ID: 10996934
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of osteoporosis].
Lakatos P
Orv Hetil; 2003 Aug; 144(31):1551-2. PubMed ID: 14502870
[No Abstract] [Full Text] [Related]
14. Underdiagnosis and under-treatment of osteoporosis following fragility fracture.
Aboyoussef M; Vierkoetter KR
Hawaii Med J; 2007 Jul; 66(7):185-7. PubMed ID: 17879856
[TBL] [Abstract][Full Text] [Related]
15. [Raloxifene and bone quality issues].
Ohta H
Clin Calcium; 2005 Jun; 15(6):1012-9. PubMed ID: 15930716
[TBL] [Abstract][Full Text] [Related]
16. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic management of osteoprosis and osteopenia.
Alexander IM
Nurse Pract; 2009 Jun; 34(6):30-40; quiz 41. PubMed ID: 19474629
[No Abstract] [Full Text] [Related]
18. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
Kastelan D; Giljevic Z; Kraljevic I; Korsic M
Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology and implications of cancer treatment-induced bone loss.
Theriault RL
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):11-5. PubMed ID: 15202582
[TBL] [Abstract][Full Text] [Related]
20. [Transplantation and osteoporosis].
Tanaka Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():531-6. PubMed ID: 18161161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
